Long Live Partial Reprogramming.

Aging can be defined as the progressive loss of physiological integrity that leads to tissue dysfunction and increased risk for developing age-associated human pathologies, such as cancer, diabetes mellitus, cardiovascular disorders, and neurodegenerative diseases.(1) Therapeutic strategies to delay...

Descripción completa

Detalles Bibliográficos
Autores: Marión, Rosa M, Blasco, MA
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19110
Acceso en línea:http://hdl.handle.net/20.500.12105/19110
Access Level:acceso abierto
Palabra clave:Cellular Reprogramming
Induced Pluripotent Stem Cells
Descripción
Sumario:Aging can be defined as the progressive loss of physiological integrity that leads to tissue dysfunction and increased risk for developing age-associated human pathologies, such as cancer, diabetes mellitus, cardiovascular disorders, and neurodegenerative diseases.(1) Therapeutic strategies to delay or prevent aging are aimed to decrease the deleterious effects of aging and to improve the quality of life in aged individuals and eventually to extend the human life span. In addition, deep molecular understanding of the mechanisms of aging may lead to new treatments for age-related diseases. In line with this, a recent article in Cell(2) shows that cyclic induction of Yamanaka reprogramming factors in vitro, what the authors called "partial reprogramming," reduces age-associated features in mouse and human cells. Strikingly, partial reprogramming induced in vivo in a mouse model of premature aging ameliorates some aging-associated hallmarks and extends their prematurely shortened life span. Importantly, these beneficial effects are not accompanied by dedifferentiation or loss of cellular identity. Finally, the authors show that partial in vivo reprogramming increases the regenerative capacity of physiologically aged wild-type mice.